Ionis Pharmaceuticals IONS Increase (Decrease) in Other Employee-Related Liabilities
Increase (Decrease) in Other Employee-Related Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's increase (decrease) in other employee-related liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's increase (decrease) in other employee-related liabilities?
- Ionis Pharmaceuticals (IONS) reported increase (decrease) in other employee-related liabilities of -$80.19M in Q1 2026.
- How has Ionis Pharmaceuticals's increase (decrease) in other employee-related liabilities changed year-over-year?
- Ionis Pharmaceuticals's increase (decrease) in other employee-related liabilities decreased by 86.3% year-over-year, from -$43.04M to -$80.19M.
- What does increase (decrease) in other employee-related liabilities mean?
- The net change in money owed to employees for earned but unpaid compensation.
- How do you interpret increase (decrease) in other employee-related liabilities?
- An increase suggests higher accrued obligations, while a decrease indicates that accrued employee costs have been settled.
- How does increase (decrease) in other employee-related liabilities compare across companies?
- Common in human-capital-intensive industries like biotech; peers will show similar seasonal patterns based on compensation cycles.